Haruyasu Murakami

27PUBLICATIONS
86CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 01, 2026
Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non-Small Cell Lung Cancer: A Single-Institution Retrospective Study.

|Apr 25, 2026
Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations.

|Nov 17, 2025
Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.

Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya

|Jun 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.

Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su

|Jun 20, 2025
Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.

Michitoshi Yabe, Tateaki Naito, Suguru Matsuda

|May 21, 2025
Desensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer.

Naoya Nishioka, Tateaki Naito, Takashi Sugino

Pageof 5

Frequent Collaborators

13 joint publications

Tateaki Naito

6 joint publications

Hirotsugu Kenmotsu

6 joint publications

Toshiaki Takahashi

6 joint publications

Kazushige Wakuda